| Description | Creative Biolabs' Neuropathy Frozen Tissue Panels are designed for the study of Alzheimer's disease, Parkinson's disease, dementia, multiple sclerosis, progressive supranuclear palsy (PSP) and depression. | This product GTTS-WQ4170MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research. | This product GTTS-WK5188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the MAGE-A4 protein. This product can be used in -related researches. | This product is recombinant Human GLUT1 in VLPs form. This product is produced from mammalian cells by co-expressing the retroviral structural core polyprotein (gag) and the target membrane protein. MP-VLPs display highly-expressed copies of membrane proteins in their native conformation, providing This product is recombinant Human GLUT1 in VLPs form. This product is produced from mammalian cells by co-expressing the retroviral structural core polyprotein (gag) and the target membrane protein. MP-VLPs display highly-expressed copies of membrane proteins in their native conformation, providing an alternative to membrane protein stable cell lines, membrane preparations, detergent-solubilized proteins and other membrane protein preparation strategies. MP-VLPs can be used for a wide range of applications in antibody production, antibody discovery, antibody characterization, binding assays and functional assays.... Read More | The product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNAThe product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-deoxy-2_-fluoro (2'-F) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |